论文部分内容阅读
目的探讨肺癌伴恶性胸水患者的治疗方案。 方法 5 7例肺癌伴恶性胸水患者 ,手术治疗组 2 9例 ,按手术、免疫、化疗序列施治 ;非手术组 2 8例 ,按免疫、介入或化疗、放疗序列施治。 结果手术组的 2 9例胸水全部消失 ,平均生存期 >1 4个月 ;非手术组的 2 8例中 2 4例胸水消失或基本消失 ,4例明显减少 ,平均生存期 >9个月。结论手术消除原发病灶减少了肿瘤负荷 ,减少或推迟了远处转移 ,可有效消除胸水 ,控制胸膜病变。介入治疗除局部药物高浓度外 ,还能闭塞肿瘤滋养血管 ,定期更换化疗方案提高化疗效果。
Objective To investigate the treatment of lung cancer patients with malignant pleural effusion. Methods Fifty-seven patients with lung cancer and malignant pleural effusion were treated with surgical treatment in 29 cases, treated by surgery, immunization, and chemotherapy. In the non-surgical group, 28 cases were treated by immunization, intervention or chemotherapy, and radiotherapy. Results Twenty-nine cases of pleural effusion in the surgical group disappeared with an average survival period of >1 4 months. In 28 non-surgical groups, 24 cases of pleural effusion disappeared or almost disappeared, and 4 cases significantly decreased. The average survival period was >9 months. Conclusion The elimination of primary lesions by surgery reduces the tumor burden, reduces or postpones distant metastasis, effectively eliminates pleural effusion and controls pleural lesions. Interventional treatment, in addition to high concentrations of local drugs, can also occlude tumors to nourish blood vessels, and regularly replace chemotherapy regimens to improve the efficacy of chemotherapy.